Abstract
New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae is increasingly reported worldwide. Clinicians face significant challenges in the treatment of this multidrug-resistant bacterium. The combination of ceftazidime/avibactam (CAZ/AVI) and aztreonam (ATM) is currently probably the most effective strategy for the treatment of such infection. We described a patient diagnosed with NK/T cell lymphoma who underwent autologous hematopoietic stem cell transplantation (ASCT) in the hematology department. The patient developed severe infection after ASCT. Blood and stool cultures showed carbapenem-resistant K. pneumoniae. Blood sample was detected as NDM-producing K. pneumoniae. We successfully treated this infection with CAZ/AVI and ATM.
Keywords: Carbapenem-resistant Klebsiella pneumoniae, Ceftazidime/avibactam aztreonam, New Delhi metallo-beta-lactamase
Introduction
With the worldwide prevalence of multidrug-resistant bacteria, people have faced increasing concerns about infections that are not treated with susceptible antibacterial agents. According to data from the US Centers for Disease Control and Prevention, the infection rate of carbapenem-resistant Enterobacteriaceae (CRE) was 57/100,000, and the in-hospital mortality rate of nosocomial infection caused by CRE is 33.50%, among which the mortality rate of blood flow infection caused by CRE is as high as 43.10% [1]. CRE infection imposes a heavy burden on patients, and the cost of treatment is higher than the annual cost of many acute and chronic diseases [2]. Due to the use of antibiotics in the early stage and the inhibition of immune function after chemotherapy, the detection rate of carbapenem-resistant K. pneumoniae (CRKP) in patients with hematological malignancies is increasing, which has seriously endangered the life of the patients [3].
New Delhi metallo-beta-lactamase (NDM)-producing K. pneumoniae was first identified in India [4]. Ceftazidime/avibactam (CAZ/AVI) can be used to treat CRKP infection, but the drug lacks activity against NDM. Whereas aztreonam (ATM) is hydrolytically stable to class B MBL [5, 6]. The combination of ATM and CAZ/AVI has been reported to be effective for the treatment of infections caused by Enterobacteriaceae producing MBL. We describe the successful treatment of a patient with the CAZ/AVI and ATM combination below.
Case presentation
In August 2021, a 62-year-old man diagnosed with NK/T-cell lymphoma was hospitalized in the hematology department for autologous hematopoietic stem cell transplantation (ASCT). On the 3rd day after ASCT, the patient developed fever and diarrhea. We gave imipenem/cilastatin 500 mg Q6H IV and teicoplanin 400 mg Q12H IV for empirical anti-infection treatment. After 2 days of treatment, the patient still had a high fever, and watery yellowish stool more than 10 times per day. On the 5th day after ASCT, the antibiotic regimen consisting of imipenem/cilastatin and teicoplanin was replaced by tigecycline 100 mg Q12H IV and cefoperazone/sulbactam 2.0 g Q8H IV. On the 6th day after ASCT, the patient was transferred to ICU due to septic shock.
We administered imipenem/cilastatin 500 mg Q4H IV and CAZ/AVI 2.5 g Q8H IV and teicoplanin 600 mg Q12H IV to anti-infective therapy. On the 3rd day of hospitalization in the ICU, K. pneumoniae was detected in blood culture (Table 1) and stool culture (Table 2) obtained from the patient on 6th after ASCT. Blood sample was detected to produce NDMCRKP by CARBA5 carbapenem detection reagent (Fig. 1). We started ATM 2.0 g Q8H IV and CAZ/AVI 2.5 g Q8H IV as antibiotic regimen. The patient’s clinical condition improved quickly after the introduction of this treatment regimen.
Table 1.
Resistance profile of Klebsiella pneumoniae strains found in blood samples
| Antibiotics | Result | MIC |
|---|---|---|
| Amikacin | Susceptible | ≦2 |
| Aztreonam | Resistant | 32 |
| Ceftazidime | Resistant | ≧64 |
| Cefoperazone/sulbactam | Resistant | ≧64 |
| Ciprofloxacine | Resistant | ≧4 |
| Doxycycline | Resistant | ≧16 |
| Cefepime | Resistant | ≧32 |
| Imipenem | Resistant | ≧16 |
| Levofloxacin | Resistant | ≧8 |
| Meropenem | Resistant | ≧16 |
| Minocycline | Resistant | ≧16 |
| Ceftazidime/Avibactam | Resistant | |
| Tobramycin | Resistant | ≧16 |
| Cotrimoxazole | Resistant | ≧320 |
| Piperacilline/Tazobactam | Resistant | ≧128 |
| Polymyxin E | Susceptible | ≦0.5 |
Table 2.
Resistance profile of Klebsiella pneumoniae strains found in stool samples
| Antibiotics | Result | MIC |
|---|---|---|
| Amikacin | Susceptible | 8 |
| Aztreonam | Resistant | 32 |
| Ceftazidime | Resistant | ≧64 |
| Cefoperazone/sulbactam | Resistant | ≧64 |
| Ciprofloxacine | Resistant | ≧4 |
| Doxycycline | Resistant | ≧16 |
| Cefepime | Resistant | ≧32 |
| Imipenem | Resistant | ≧16 |
| Levofloxacin | Resistant | ≧8 |
| Meropenem | Resistant | ≧16 |
| Minocycline | Resistant | ≧16 |
| Ceftazidime/Avibactam | Resistant | |
| Tobramycin | Resistant | ≧16 |
| Cotrimoxazole | Resistant | ≧320 |
| Piperacilline/Tazobactam | Resistant | ≧128 |
| Polymyxin E | Susceptible | ≦0.5 |
Fig. 1.
CARBA5 carbapenem detection reagent
Discussion
New Delhi metallo-beta-lactamase-1 (NDM-1) is a metal-ion-dependent β-lactamase (MBL), and bacteria carrying this enzyme can hydrolyze almost all β-lactam antibiotics, but ATM cannot form a productive complex with MBLs. ATM is a monocyclic β-lactam antibiotic that is active against MBL-producing enzymes, but can be hydrolyzed by extended-spectrum β-lactamases. Avibactam can protect ATM from being hydrolyzed by class A and class C β-lactamases, thereby retaining the attack activity of ATM against class B metalloenzyme-producing Enterobacteriaceae [7].
Marshall et al. demonstrated coordinated bactericidal effects of CAZ/AVI in combination with ATM against multiple Enterobacteriaceae with MBLs in 17/21 isolates. In a murine neutropenic thigh infection model, compared with CAZ/AVI alone, CAZ/AVI plus ATM reduced CFUs by almost 4log10 at 24 h post-dose [7]. Maraki and his colleagues assessed the in vitro synergy of ATM in combination with CAZ/AVI against 40 MDR, MBL-producing, and serine-β-lactamase-producing K. pneumoniae strains by an Etest-based synergy approach, with synergy observed in 97.5% of the CAZ/AVI-ATM combination group [8]. Jayol A et al. recovered 63 K. pneumoniae isolates from clinical samples. Among them, 15 strains are NDM-like producers. The combination of CAZ/AVI and ATM was found to be particularly effective against NDM-producing K. pneumoniae using MIC test strips [9]. Falcone et al. found that CAZ/AVI combined with ATM (19.2%) had a lower 30-day mortality rate than other single antibiotics or combinations (44%) in a prospective study [10].
Bocanegra-Ibarias et al. reported a case of aplastic anemia patient with agranulocytosis and bloodstream infection after chemotherapy. The blood culture result was K. pneumoniae with NDM-1, which was successfully treated with ATM and CAZ/AVI [11]. Perrotta and colleagues also reported successful treatment of K. pneumoniae NDM sepsis and intestinal decolonization with ATM in combination with CAZ/AVI in a patient with TTP and SARS-CoV-2 nosocomial infection [12].
Currently, there are few case reports on CAZ/AVI combined with ATM in the treatment of MBL-producing K. pneumoniae infection in China. The CAZ/AVI + ATM combination overcame MBL/NDM producing K. pneumoniae by bypassing the most important resistance determinants.
Conclusions
CAZ/AVI combined with ATM is currently an effective treatment option for MBL-producing microbial infections.
Author contribution
HJ, CJ, and LZ contributed to drafting of the manuscript. QQ reactively participated in diagnosis, treatment, and responsible for polishing the English translation.SY contributed to critical revision of the final version. All authors approved the final version of the manuscript.
Data availability
Not applicable.
Code availability
Not applicable.
Declarations
Ethics approval
Ethics approval for this study was waived by the local ethics committee at Hospital of Ningbo University because it is a single-case study.
Consent to participate
Written informed consent was obtained from the patient.
Consent for publication
The participant has consented to the submission of the case report to the journal.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.van Duin D, Arias CA, Komarow L, Chen L, Hanson BM, Weston G, Cober E, Garner OB, Jacob JT, Satlin MJ, Fries BC, Garcia-Diaz J, Doi Y, Dhar S, Kaye KS, Earley M, Hujer AM, Hujer KM, Domitrovic TN, Shropshire WC, Dinh A, Manca C, Luterbach CL, Wang M, Paterson DL, Banerjee R, Patel R, Evans S, Hill C, Arias R, Chambers HF, Fowler VG, Jr, Kreiswirth BN, Bonomo RA, Multi-Drug Resistant Organism Network I Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2) a prospective cohort study. The Lancet Infectious diseases. 2020;20(6):731–741. doi: 10.1016/S1473-3099(19)30755-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Otter JA, Burgess P, Davies F, Mookerjee S, Singleton J, Gilchrist M, Parsons D, Brannigan ET, Robotham J, Holmes AH. Counting the cost of an outbreak of carbapenemase-producing Enterobacteriaceae: an economic evaluation from a hospital perspective. Clin Microbiol Infect. 2017;23(3):188–196. doi: 10.1016/j.cmi.2016.10.005. [DOI] [PubMed] [Google Scholar]
- 3.Zhang P, Wang J, Hu H, Zhang S, Wei J, Yang Q, Qu T. Clinical Characteristics and Risk Factors for Bloodstream Infection Due to Carbapenem-Resistant Klebsiella pneumoniae in Patients with Hematologic Malignancies. Infect Drug Resist. 2020;13:3233–3242. doi: 10.2147/IDR.S272217. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53(12):5046–5054. doi: 10.1128/AAC.00774-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Shields RK, Doi Y. Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria? Clin Infect Dis : an Off Publ Infect Dis Soc America. 2020;71(4):1099–1101. doi: 10.1093/cid/ciz1159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Drawz SM, Papp-Wallace KM, Bonomo RA. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58(4):1835–1846. doi: 10.1128/AAC.00826-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Bonomo RA (2017) Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in enterobacteriaceae?. Antimicrobial agents and chemotherapy 61(4):e02243–16 [DOI] [PMC free article] [PubMed]
- 8.Maraki S, Mavromanolaki VE, Moraitis P, Stafylaki D, Kasimati A, Magkafouraki E, Scoulica E. Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-beta-lactamase-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis. 2021;40(8):1755–1759. doi: 10.1007/s10096-021-04197-3. [DOI] [PubMed] [Google Scholar]
- 9.Jayol A, Nordmann P, Poirel L, Dubois V. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73(2):542–544. doi: 10.1093/jac/dkx393. [DOI] [PubMed] [Google Scholar]
- 10.Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, Leonildi A, Tagliaferri E, Barnini S, Sani S, Farcomeni A, Ghiadoni L, Menichetti F. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-beta-lactamase-Producing Enterobacterales. Clin Infect Dis. 2021;72(11):1871–1878. doi: 10.1093/cid/ciaa586. [DOI] [PubMed] [Google Scholar]
- 11.Bocanegra-Ibarias P, Camacho-Ortiz A, Garza-Gonzalez E, Flores-Trevino S, Kim H, Perez-Alba E. Aztreonam plus ceftazidime-avibactam as treatment of NDM-1-producing Klebsiella pneumoniae bacteraemia in a neutropenic patient: Last resort therapy? J Glob Antimicrob Resist. 2020;23:417–419. doi: 10.1016/j.jgar.2020.10.019. [DOI] [PubMed] [Google Scholar]
- 12.Perrotta F, Perrini MP (2021) Successful treatment of klebsiella pneumoniae NDM sepsis and intestinal decolonization with ceftazidime/avibactam plus aztreonam combination in a patient with TTP complicated by SARSCoV-2 nosocomial infection. Medicina (Kaunas, Lithuania) 57(5):424 [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Not applicable.
Not applicable.